Fluoxetine is an SSRI, or selective serotonin reuptake inhibitor. It was the first SSRI approved in the United States, receiving FDA clearance on December 29, 1987, under the brand name Prozac. It remains one of the most widely prescribed antidepressants in the world and is approved for use in both adults and children.
How Fluoxetine Works as an SSRI
SSRIs work by blocking the reabsorption of serotonin in the brain. Normally, after serotonin delivers a signal between nerve cells, it gets pulled back into the sending cell and recycled. Fluoxetine prevents that recycling step, which leaves more serotonin available in the gap between nerve cells. Over time, this increase in available serotonin helps regulate mood, anxiety, and certain behavioral patterns.
This mechanism is what defines the entire SSRI class. Other SSRIs include sertraline (Zoloft), escitalopram (Lexapro), paroxetine (Paxil), and citalopram (Celexa). They all target serotonin reabsorption, though they differ in how long they stay in the body, how they interact with other medications, and which conditions they’re approved to treat.
What Makes Fluoxetine Unique Among SSRIs
Fluoxetine stands out from other SSRIs primarily because of how long it stays active in your system. After you take it regularly, the drug itself has a half-life of 4 to 6 days. It also produces an active byproduct called norfluoxetine, which continues working for 4 to 16 days. This means that even after you stop taking fluoxetine, the active compounds remain in your body for weeks.
This long duration is a double-edged feature. On one hand, it makes fluoxetine more forgiving if you miss a dose. You’re less likely to experience the withdrawal-like discontinuation symptoms that can happen with shorter-acting SSRIs like paroxetine. On the other hand, it means that when you stop the medication or switch to something else, you need to account for the fact that fluoxetine is still doing its job in your body for a significant period afterward.
FDA-Approved Uses
Fluoxetine has a broader range of approved uses than many other SSRIs. In adults, it is approved for:
- Major depressive disorder (both short-term and ongoing maintenance treatment)
- Obsessive-compulsive disorder (OCD)
- Panic disorder, with or without agoraphobia
- Bulimia nervosa (specifically for reducing binge-eating and purging behaviors)
For children and adolescents, fluoxetine is FDA-approved for depression in patients ages 8 and older, and for OCD in patients ages 7 and older. It is one of the few antidepressants with pediatric approval.
Fluoxetine can also be used in combination with olanzapine for two additional conditions: depressive episodes associated with bipolar I disorder (in adults and children ages 10 to 17) and treatment-resistant depression in adults who haven’t responded to at least two other antidepressants. Fluoxetine alone is not approved for either of those conditions.
Common Side Effects
In a survey of roughly 700 patients taking SSRIs, about 38% reported experiencing at least one side effect. The three most frequently mentioned were changes in sexual functioning, sleepiness, and weight gain. These are consistent across the SSRI class, not unique to fluoxetine.
The good news is that most people don’t find these effects severe. Among those who did report side effects, only about 26% described them as “very bothersome” or “extremely bothersome.” Many side effects also diminish during the first few weeks of treatment as the body adjusts. That said, sexual side effects tend to be more persistent and are one of the most common reasons people discuss switching medications with their prescriber.
Drug Interactions to Be Aware Of
Because fluoxetine boosts serotonin levels, combining it with other substances that also raise serotonin can push levels dangerously high, creating a condition called serotonin syndrome. Symptoms range from agitation, rapid heartbeat, and diarrhea to muscle rigidity, seizures, and high fever in severe cases.
The drug classes most likely to cause problems when combined with fluoxetine include MAOIs (an older class of antidepressants), tricyclic antidepressants, and certain pain medications like tramadol and meperidine. The anti-nausea drug ondansetron, the mood stabilizer lithium, and some antihistamines have also been linked to elevated serotonin. Recreational drugs like MDMA (ecstasy) and cocaine carry serious risk as well.
Fluoxetine also affects a liver enzyme called CYP2D6, which the body uses to break down many other medications. This means fluoxetine can cause other drugs to build up to higher-than-expected levels in your bloodstream, potentially increasing their side effects. This is especially relevant for people taking multiple prescriptions.
Fluoxetine During Pregnancy and Breastfeeding
Fluoxetine is one of the most studied SSRIs during pregnancy and breastfeeding, though the picture is nuanced. During breastfeeding, fluoxetine passes into breast milk at higher levels than most other SSRIs. The active byproduct norfluoxetine is detectable in the blood of most breastfed infants during the first two months. In studies measuring both compounds, infants received an estimated 7% of the mother’s weight-adjusted dose through breast milk (ranging from 3% to 12%).
Despite these numbers, studies following infants up to 5 years of age have found no adverse effects on development. In one study of 29 mothers taking an average of about 35 mg daily, infants who were exclusively breastfed for four months had normal weight gain. Most experts recommend that if a mother was already taking fluoxetine during pregnancy or if other antidepressants haven’t worked, switching medications during breastfeeding isn’t necessary. For mothers starting a new antidepressant while nursing a newborn or preterm infant, SSRIs with lower breast milk excretion may be preferred.
Breastfed infants should be monitored for behavioral changes like unusual fussiness, poor feeding, or slow weight gain. There’s also some evidence that mothers taking an SSRI during pregnancy and postpartum may have more difficulty with breastfeeding itself, though researchers note this could reflect the underlying depression rather than a direct drug effect. One encouraging finding: breastfed infants who were exposed to an SSRI during the third trimester actually had a lower risk of poor neonatal adaptation compared to formula-fed infants with the same exposure.